Sanofi, Regeneron announce positive Phase 2a study results of asthma drug
The study of the IL-4R alpha inhibitor demonstrated 87% reduction in risk of asthma exacerbations in moderate-to-severe asthma patients with elevated eosinophils. Trial lead investigator and the University